PBR vs PRTG

Petroleo Brasileiro S.A. Petrobras

Petróleo Brasileiro S.A. - Petrobras produce and sells oil and gas in Brazil and internationally. It engages in prospecting, drilling, refining, processing, trading, and transporting crude oil from producing onshore and offshore oil fields, and shale or other rocks, as well as oil products, natural gas, and other liquid hydrocarbons. The company operates through Exploration and Production; Refining, Transportation and Marketing; Gas and Power; and Corporate and Other Businesses segments. The Exploration and Production segment explores for, develops, and produces crude oil, natural gas liquids, and natural gas primarily for supplies to the its domestic refineries. The Refining, Transportation and Marketing segment engages in the refining, logistics, transport, marketing, and trading of crude oil and oil products; exportation of ethanol; and extraction and processing of shale, as well as holding interests in petrochemical companies. The Gas and Power segment engages in the logistic and trading of natural gas and electricity; generation of electricity through thermoelectric power plants; holding interests in transportation and distribution of natural gas; and fertilizer production business. The Corporate and Other Businesses segment produces biodiesel and its co-products, and ethanol; and distributes oil products. Petróleo Brasileiro S.A. - Petrobras was founded in 1953 and is headquartered in Rio de Janeiro, Brazil.

Portage Biotech Inc.

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.